Skip to main content
SpringerLink
Log in

Diagnosis and Treatment of Gastric Cancer

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Despite a decreased incidence, gastric cancer remains a leading cause of death worldwide. The only potentially curative modality for localised gastric cancer is surgery. However, overall 5-year survival does not exceed 40%. Although extensive surgery seems to increase survival in Japanese patients, this has not yet been demonstrated in Western patients. The pattern of recurrence of gastric cancer would suggest that both local and systemic treatment are required to improve survival. To date, there is no evidence that adjuvant treatment is effective.

Some trials investigating preoperative chemotherapy with various combinations of etoposide, fluorouracil, cisplatin and doxorubicin in locally advanced disease suggest that a reduction in the bulk of the localised tumour may increase the curative resection rate.

Advanced disease remains poorly controlled. The most effective treatments appear to be a combination of fluorouracil, methotrexate and doxorubicin (FAMTX), and of fluorouracil and cisplatin. Response rates range from 25 to 50%, and median survival from 6 to 13 months. New agents and new therapeutic approaches are required to improve the poor prognosis of gastric cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alexander HR, Kelsen DP, Tepper JE. Cancer of the stomach. In: Devita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles of oncology. 4th ed. Philadelphia: JB Lippincott Co., 1993: 818–48

    Google Scholar 

  2. Bleiberg H, Deguiral Ph, Gerard B. Adjuvant therapy in resectable gastric cancer. Br J Cancer 1992; 66: 987–91

    Article  PubMed  CAS  Google Scholar 

  3. Wils J, Bleiberg H. Current status of chemotherapy for gastric cancer. Eur J Cancer Clin Oncol 1989; 25: 3–8

    Article  PubMed  CAS  Google Scholar 

  4. Grimm H, Binmoeller KF, Koch J, et al. Endosonography for preoperative locoregional staging of esophageal and gastric cancer. Endoscopy 1993; 25: 224–30

    Article  PubMed  CAS  Google Scholar 

  5. Rosh T, Classen M. Gastroenterologic endosonography. Textbook and atlas. New York: Georg Thieme Verlag, 1992: 76–7

    Google Scholar 

  6. Macdonald JS, Hill MC, Roberts IM. Gastric cancer: epidemiology, pathology, detection and staging. In: Ahlgren JD, Macdonald JS, editors. Gastrointestinal oncology. Philadephia: JB Lippincott Co., 1992: 151–7

    Google Scholar 

  7. Hildebrandt V, Feifel G. Endosonography in the diagnosis of lymph nodes. Endoscopy 1993; 25: 243–5

    Article  PubMed  CAS  Google Scholar 

  8. Smith JW, Brennan MF, Botet JF, et al. Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma. J Clin Oncol 1993; 12: 2380–5

    Google Scholar 

  9. Beahrs O, Myers M, editors. The manual for staging of cancer. 2nd ed. Philadephia: JB Lippincott Co., 1983: 30

    Google Scholar 

  10. Gunderson L, Sosin H. Adenocarcinoma of the stomach. Areas of failure in a retrospective series (second or symptomatic look). Clinico pathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8: 1–11

    CAS  Google Scholar 

  11. Vezeridis MP, Wanebo HJ. Gastric cancer: surgical approach. In: Ahlgren JD, Macdonald JS, editors. Gastrointestinal oncology. Philadelphia: JB Lippincott Co., 1992: 159–69

    Google Scholar 

  12. Behrns KE, Dalton RR, van Heerden JA, et al. Extended lymph node dissection for gastric cancer. Is it of value?. Gastric Surg 1992; 72: 433–43

    CAS  Google Scholar 

  13. Bollschweiler E, Boettcher K, Hoelscher AH, et al. Is the prognosis for Japanese and German patients with gastric cancer really different?. Cancer 1993; 71: 2918–25

    Article  PubMed  CAS  Google Scholar 

  14. Bunt AMG, Hermans J, Boon MC, et al. Evaluation of the extent of lymphadenectomy in a randomized trial of Western-versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994; 12: 417–22

    PubMed  CAS  Google Scholar 

  15. Nitti D, Lise M, Marchet A, et al. Prognostic factors in resectable gastric cancer: results of the EORTC study (40813) on FAM adjuvant chemotherapy. J Cancer Res Clin Oncol 1994; 120 Suppl.: R73

    Google Scholar 

  16. Brems-Dalgaard E, Clause HV. Survival following microscopically confirmed radical resection of NO gastric cancer. Br J Surg 1993; 80: 1150–2

    Article  PubMed  CAS  Google Scholar 

  17. Siewert JR, Bôttcher K, Roder JD, et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993; 80: 1015–8

    Article  PubMed  CAS  Google Scholar 

  18. Collins WJ, Gall EA. Gastric carcinoma. A multicentric lesion. Cancer 1952; 5: 562–72

    Google Scholar 

  19. Gouzi JL, Juguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Ann Surg 1989; 209: 162–6

    Article  PubMed  CAS  Google Scholar 

  20. Buhl Schlag P, Herfarth C. Quality of life and functional results following different types of resection for gastric carcinoma. Eur J Surg Oncol 1990; 16: 404–9

    Google Scholar 

  21. Viste A, Haugstvedt T, Eide GE, et al. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1981; 207: 7–13

    Article  Google Scholar 

  22. Noguchi Y, Imada T, Matsumoto A, et al. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989; 64: 2053–62

    CAS  Google Scholar 

  23. Sugimachi K, Kodama Y, Kumashiro R, et al. Critical evaluation of prophylactic splenectomy in total gastrectomy for the stomach cancer. Japanese Journal of Cancer Research 1980; 71: 704–9

    CAS  Google Scholar 

  24. Brady MS, Rogatko A, Dent LL, et al. Effect of splectomy on morbidity and survival following curative gastrectomy for carcinoma. Arch Surg 1991; 126: 359–64

    Article  PubMed  CAS  Google Scholar 

  25. Moertel CG, Childs DS, Reitemeier R, et al. Combined 5-FU and supervoltage radiation therapy of locally unresectable gastro-intestinal cancer. Lancet 1969; 2: 865–7

    Article  PubMed  CAS  Google Scholar 

  26. Dent D, Werner I, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979; 44: 385–91

    Article  PubMed  CAS  Google Scholar 

  27. Moertel C, Childs D, O’Fallon J, et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984; 2: 1249–54

    PubMed  CAS  Google Scholar 

  28. Abe M, Takashashi M. Intraoperative radiotherapy: the Japanese experience. Int J Radiat Oncol Biol Phys 1981; 7: 863–8

    Article  PubMed  CAS  Google Scholar 

  29. Sindelar W, Kinsella T. Randomized trial of resection and intraoperative radiotherapy in locally advanced gastric cancer. Proc Am Soc Clin Oncol 1987; 28: 91

    Google Scholar 

  30. Schein PH. Gastric cancer: approaches to adjuvant therapy. In: Ahlgren JD, Macdonald JS, editors. Gastrointestinal oncology. Philadelphia: JB Lippincott Co., 1992: 189–93

    Google Scholar 

  31. Bleiberg H, Goffin JC, Dalesio O, et al. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer: a randomized trial of the Gastrointestinal Tract Cancer Cooperative Group of the EORTC. Eur J Surg Oncol 1989; 15: 535–43

    PubMed  CAS  Google Scholar 

  32. Koyama S, Ozaki A, Iwasaki Y, et al. Randomized controlled study of postoperative adjuvant immunochemotherapy with nocardia rubra cell wall skeleton (NCWS) and tegafur for gastric carcinoma. Cancer Immunol Immunother 1986; 22: 148–54

    Article  PubMed  CAS  Google Scholar 

  33. Youn J, Kim B, Min J, et al. Adjuvant treatment of operable stomach cancer with polyadenylic polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. Int J Immunopharmacol 1990; 12: 289–95

    Article  PubMed  CAS  Google Scholar 

  34. Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990; 45: 169–72

    Article  PubMed  CAS  Google Scholar 

  35. Harrisson JD, Morris DL, Ellis IO, et al. The effect of tamoxifen on survival in gastric carcinoma. Cancer 1989; 64: 1007–10

    Article  Google Scholar 

  36. Tonnesen H, Bulow S, Fisherman K, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988; 2: 990–1

    Article  PubMed  CAS  Google Scholar 

  37. Alcobendas F, Milla A, Estape J, et al. Mitomycin C as an adjuvant in resected gastric cancer. Ann Surg 1983; 198: 13–7

    Article  PubMed  CAS  Google Scholar 

  38. The Gastrointestinal Tumour Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116–22

    Article  Google Scholar 

  39. Ochiai T, Sato H, Hayashi R, et al. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. Cancer Immunol Immunother 1983; 14: 167–71

    Article  PubMed  CAS  Google Scholar 

  40. Estape J, Grau J, Alcobendas F, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. Ann Surg 1991; 213: 219–21

    Article  PubMed  CAS  Google Scholar 

  41. Higgins GA, Amadea JH, Smith DA, et al. Intermittent therapy with combined 5FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1989; 52: 1105–12

    Article  Google Scholar 

  42. Engstrom PF, Lavin PT, Douglass HO, et al. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 1985; 55: 1868–73

    Article  PubMed  CAS  Google Scholar 

  43. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441–7

    PubMed  CAS  Google Scholar 

  44. Hermans J, Bonenkamp JJ. In reply to: ‘Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal’ and to ‘Meta-analysis need time, collaboration, and funding’ [letter]. J Clin Oncol 1994; 12: 879–80

    Google Scholar 

  45. Murthy S, Goldschmidt R, Rao L, et al. The influence of surgical trauma on experimental metastasis. Cancer 1989; 64: 2035–44

    Article  PubMed  CAS  Google Scholar 

  46. Archer S, Grey B. Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micro-metastasis. Surgery 1990; 108: 502–7

    PubMed  CAS  Google Scholar 

  47. Sugarbaker P, Gianola F, Speyer J, et al. Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with primary colon or rectal cancer. Surgery 1985; 98: 414–21

    PubMed  CAS  Google Scholar 

  48. Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629–31

    Article  PubMed  CAS  Google Scholar 

  49. Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res 1989; 49: 1996–2001

    PubMed  CAS  Google Scholar 

  50. Ajani JA, Roth JA, Ryan B, et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990; 8: 1231–8

    PubMed  CAS  Google Scholar 

  51. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative chemotherapy for potentially resectable gastric carcinoma. J Nat Cancer Inst 1993; 85: 1839–44

    Article  PubMed  CAS  Google Scholar 

  52. Rougier Ph, Lasser Ph, Ducreux M, et al. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994; 5: S59–568

    Google Scholar 

  53. Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and non resectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989; 7: 1318–26

    PubMed  CAS  Google Scholar 

  54. Macdonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, mitomycin C, and Adriamycin(FAM): a new combination chemotherapy program for advanced gastric carcinoma. Ann Intern Med 1980; 93: 533–6

    PubMed  CAS  Google Scholar 

  55. Preusser P, Achterrath W, Wilke H, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988; 15: 257–77

    Article  PubMed  CAS  Google Scholar 

  56. Cullinam SA, Moertel CG, Flemeing TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma JAMA 1985; 253: 2061–7

    Article  Google Scholar 

  57. Lacave AJ, Izarzugaza J, Anton Aparicio LM, et al. Phase II clinical trial of cis-dichlarodiamine platinum in gastric cancer. Am J Clin Oncol 1983; 6: 35–8

    PubMed  CAS  Google Scholar 

  58. Cunningham D, Cahn A, Menzies-Gow N. Cisplatin, epirubicin and 5-fluorouracil(CEF) has significant activity in advanced gastric cancer. Proc Am Soc Clin Oncol 1990; 9: 123

    Google Scholar 

  59. Lacave AJ, Wils J, Diaz-Rubio E, et al. Cis-platinum as second-line chemotherapy in advanced gastric carcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Clin Oncol 1985; 21: 1321–4

    CAS  Google Scholar 

  60. Kim NK, Park YS, Suh CJ, et al. Phase III randomized comparison of 5-FU vs FAM (5-FU/ADRIA/MMC) vs FP(5-FU/Cisplatin) in patients with advanced gastric carcinoma (AGC). Proc Am Soc Clin Oncol 1991; 10: 144

    Google Scholar 

  61. Preusser P, Wilke H, Achtermath W, et al. A phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310–7

    PubMed  CAS  Google Scholar 

  62. Wilke H, Preusser P, Fink U, et al New developments in the treatment of gastric carcinoma. Sem Oncol 1990; 17: 61–70

    CAS  Google Scholar 

  63. Klein HO. Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. Cancer Res 1989; 9: 1025–6

    CAS  Google Scholar 

  64. Wils J, Bleiberg H, Dalesio O, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986; 4: 1799–803

    PubMed  CAS  Google Scholar 

  65. Wils JA, Klein HO, Wagener DJTH, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin- A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827–31

    CAS  Google Scholar 

  66. Kelsen D, Atiq O, Saltz L, et al. FAMTX (5-fluorouracil, Adriamycin, methotrexate) is as effective and less toxic than EAP (etoposide, methotrexate, Adriamycin): a random assignment trial in gastric cancer. Proc Am Soc Clin Oncol 1991; 10: 137

    Google Scholar 

  67. Murad AM, Santiago AF, Petzoianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41

    Article  PubMed  CAS  Google Scholar 

  68. Lavin PT, Bruckner HW, Plaxe SC, et al. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 1982; 50: 2016–23

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology and Chemotherapy Unit, Internal Medicine Department, Centre des Tumeurs de l’Université Libre de Bruxelles, Institut Jules Bordet, Rue Héger-Bordet 1, 1000, Brussels, Belgium

    Alain Hendlisz &  Harry Bleiberg

Authors
  1. Alain Hendlisz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry Bleiberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hendlisz, A., Bleiberg, H. Diagnosis and Treatment of Gastric Cancer. Drugs 49, 711–720 (1995). https://doi.org/10.2165/00003495-199549050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549050-00006

Keywords

Search

Navigation